Skip to main content
. 2023 Dec 15;13(1):e230108. doi: 10.57264/cer-2023-0108

Figure 5. . Treatments received by commercial and Medicare patients from index to first myasthenia gravis exacerbation and between exacerbations during 2-year follow-up.

Figure 5. 

‘Biologics’ includes rituximab and eculizumab.

AChEI: Acetylcholinesterase inhibitor; CS: Corticosteroid; IVIg: Intravenous immunoglobulin; NSIST: Non-steroidal immunosuppressive therapy; PLEX: Plasma exchange.